Skip to main content

Dermata Therapeutics, Inc. (DRMA)

NASDAQ: DRMA · Delayed Price · USD
4.16
-0.01 (-0.24%)
Pre-market:Sep 20, 2021 7:32 AM EDT
4.17
-0.03 (-0.71%)
At close: Sep 17, 4:00 PM
Market Cap34.24M
Revenue (ttm)n/a
Net Income (ttm)-4.12M
Shares Out8.21M
EPS (ttm)-0.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,164
Open4.20
Previous Close4.20
Day's Range4.17 - 4.39
52-Week Range4.14 - 6.50
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About DRMA

Dermata Therapeutics is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Our Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris, or Spongilla. Traditionally, locals would harvest the sponge to be used as a folk medicine to treat various inflammatory ailments, but research has been conducted to evaluate the use of Spongilla for the possible treatment of various skin diseases and aesthetic conditions. Our lead product candidate, ...

IndustryBiotechnology
IPO DateAug 13, 2021
CEOGerald T. Proehl
Employees7
Stock ExchangeNASDAQ
Ticker SymbolDRMA
Full Company Profile

Financial Performance

Financial Statements

News

Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer

SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the developme...

2 weeks ago - Accesswire

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering

SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW), a clinical-stage medical dermatology company focused on identifying, developi...

1 month ago - Accesswire

Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering

Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharma...

1 month ago - AccessWire

Dermata Therapeutics IPO Registration Document (S-1)

Dermata Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC